Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711432 | 1.00 | GSK3B (1.00) | GSK3BLATS1 | |
| SCHEMBL696294 | 0.86 | GSK3B (1.00) | GSK3B | |
| SCHEMBL8231836 | 0.86 | GSK3B (1.00) | GSK3B | |
| SCHEMBL13711546 | 0.86 | GSK3B (1.00) | GSK3B | |
| SCHEMBL697412 | 0.84 | GSK3B (0.72) | GSK3BLATS1 | |
| SCHEMBL696692 | 0.84 | GSK3B (0.72) | GSK3BLATS1 | |
| SCHEMBL698539 | 0.84 | GSK3B (0.72) | GSK3BLATS1 | |
| SCHEMBL8234326 | 0.82 | GSK3B (0.73) | GSK3BLATS1 | |
| SCHEMBL696744 | 0.82 | GSK3B (0.73) | GSK3BLATS1 | |
| SCHEMBL1673639 | 0.82 | GSK3B (0.70) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | GSK3B 140/4885LATS1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.